Efficacy of a Moisturizer for Uremic Xerosis

Efficacy of a Moisturizer for Uremic Xerosis in Patients Undergoing Hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008237

Enrollment

Registered

2023-02-27

Start date

2021-01-14

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Others(moisturizer) : The test cream used in this study is BARRIEDERM CREAM MD® (Cell Fusion C, Seoul, Republic of Korea), which contains various components, including a lipid mixture (Neo-CMS®

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients who met the following criteria are enrolled: 1) undergoing maintenance hemodialysis, 2) ages between 20 and 70, and 3) complaining of discomfort due to skin dryness and itching.

Exclusion criteria

Exclusion criteria: Patients who met at least one of the following criteria are excluded: 1) in active states of dermatitis requiring systemic corticosteroids or immunosuppressants, 2) with allergic dermatitis from cosmetic usage, 3) previous treatment with topical corticosteroids within the past four weeks or 4) skin infection requiring oral or topical antimicrobial therapy.

Design outcomes

Primary

Measure	Time frame
Investigator’s Global Assessment	—

Secondary

Measure	Time frame
skin biophysical parameters (hydration, transepidermal water loss, erythema index, melanin index)	—

Countries

Korea, Republic of

Contacts

Public ContactYeon Joo Jung

Samsung Medical Center

jyj95990@naver.com+82-2-3410-1194

Outcome results